Zevra therapeutics appoints biopharma veteran wendy dixon, ph.d., to board of directors

Celebration, fla., march 30, 2023 (globe newswire) -- zevra therapeutics (nasdaqgs: zvra) (“zevra” or the “company” and formerly kempharm, inc.), a rare disease therapeutics company, today announced that it has appointed wendy l. dixon, ph.d., to the company's board of directors (the “board”), effective immediately following the conclusion of the 2023 annual meeting of stockholders (“2023 annual meeting”), to fill the vacancy resulting from dr. travis mickle's resignation from the board effective as of the day of the 2023 annual meeting to be held on april 25, 2023. dr. dixon is a seasoned biopharma executive with more than 40 years in senior leadership roles, including serving as chief marketing officer and president of global marketing at bristol myers squibb.
ZVRA Ratings Summary
ZVRA Quant Ranking